ClinicalTrials.gg

Program

icg318

A development code. Also written as “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion”, “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T” and “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T”.

Its studies are mostly in Lupus Nephritis · Myositis · Inflammatory Bowel Diseases, led by iCell Gene Therapeutics.

Furthest: phase 2, since Oct 17, 20253 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
iCell Gene Therapeutics33 open or runningphase 2since Oct 17, 2025Oct 17, 2025Dec 31, 2027phase 1 · NCT07715136

Also a collaborator on its studies: icar-bio-therapeutics-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2025First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT07328581 · 20 planned · United States
  2. Apr 8, 2026Phase 2 study in Inflammatory Bowel DiseasesNCT07544160 · 18 planned · China
  3. Jul 6, 2026Phase 1 study in MyositisNCT07715136 · 10 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in MyositisNCT07715136
  2. Apr 7, 2028Primary completion: phase 2 study in Inflammatory Bowel DiseasesNCT07544160
  3. Dec 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07328581

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07715136Myositis · China1RecruitingDec 31, 202710
NCT07544160Inflammatory Bowel Diseases · China2Not yet recruitingApr 7, 202818
NCT07328581Lupus Erythematosus, Systemic · United States2RecruitingDec 202820

How it is read

Names in the registry

  • “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion”, 1 entry
  • “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T”, 1 entry
  • “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T”, 1 entry

Codes read as this program: ICG318.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.